Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Integris Southwest Medical Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
- Integris Cancer Institute of Oklahoma — Oklahoma City, Oklahoma
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Oklahoma: - Local Institution - 0605 — Oklahoma City, Oklahoma
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Oklahoma: - GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Oklahoma: - Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Oklahoma: - Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Oklahoma: - Investigative Site — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Oklahoma: - University of Oklahoma Health Sciences, Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05379595
Sites in Oklahoma: - Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Oklahoma: - Sarah Cannon Research Institute - Oklahoma University — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Oklahoma: - OU Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other pl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05803382
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Oklahoma: - Xencor Investigative Site — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itsel…
Sponsor: Kumquat Biosciences Inc.
NCT ID: NCT06720987
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…
Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in Oklahoma: - Oklahoma University Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oklahoma: - Massive Bio SYNERGY-AI site — Tulsa, Oklahoma
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Industry
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-u…
Sponsor: Elephas
NCT ID: NCT07327489
Sites in Oklahoma: - Mercy Hospital - OKC — Oklahoma City, Oklahoma